MX2023008406A - Formulacion farmaceutica. - Google Patents
Formulacion farmaceutica.Info
- Publication number
- MX2023008406A MX2023008406A MX2023008406A MX2023008406A MX2023008406A MX 2023008406 A MX2023008406 A MX 2023008406A MX 2023008406 A MX2023008406 A MX 2023008406A MX 2023008406 A MX2023008406 A MX 2023008406A MX 2023008406 A MX2023008406 A MX 2023008406A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulation
- preparing
- pharmaceutical
- relates
- pharmaceutical formulations
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2100526.9A GB202100526D0 (en) | 2021-01-15 | 2021-01-15 | Pharmaceutical formulation |
| PCT/GB2022/050083 WO2022153062A1 (en) | 2021-01-15 | 2022-01-14 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008406A true MX2023008406A (es) | 2023-08-03 |
Family
ID=74678956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008406A MX2023008406A (es) | 2021-01-15 | 2022-01-14 | Formulacion farmaceutica. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240082244A1 (https=) |
| EP (1) | EP4277606A1 (https=) |
| JP (1) | JP2024505630A (https=) |
| KR (1) | KR20230133285A (https=) |
| CN (1) | CN116710077A (https=) |
| AU (1) | AU2022208241A1 (https=) |
| CA (1) | CA3202029A1 (https=) |
| GB (1) | GB202100526D0 (https=) |
| MX (1) | MX2023008406A (https=) |
| WO (1) | WO2022153062A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220023266A1 (en) | 2018-12-07 | 2022-01-27 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | Crf受容体アンタゴニストおよび使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA845180B (en) * | 1983-07-07 | 1986-02-26 | American Home Prod | Pharmaceutical composition containing a liquid lubricant |
| US9783550B2 (en) * | 2013-05-14 | 2017-10-10 | The Board Of Regents Of The University Of Texas System | Highly potent inhibitors of porcupine |
| KR102525131B1 (ko) * | 2014-10-08 | 2023-04-24 | 레드엑스 파마 피엘씨 | Wnt 신호 경로의 억제제로서의 N-피리디닐 아세트아미드 유도체 |
| CN111971063A (zh) * | 2018-04-06 | 2020-11-20 | 4阵营疗法公司 | 通过靶向调节基因信号传导网络治疗疾病 |
-
2021
- 2021-01-15 GB GBGB2100526.9A patent/GB202100526D0/en not_active Ceased
-
2022
- 2022-01-14 CA CA3202029A patent/CA3202029A1/en active Pending
- 2022-01-14 WO PCT/GB2022/050083 patent/WO2022153062A1/en not_active Ceased
- 2022-01-14 JP JP2023542980A patent/JP2024505630A/ja active Pending
- 2022-01-14 EP EP22701416.4A patent/EP4277606A1/en active Pending
- 2022-01-14 CN CN202280010206.5A patent/CN116710077A/zh active Pending
- 2022-01-14 MX MX2023008406A patent/MX2023008406A/es unknown
- 2022-01-14 AU AU2022208241A patent/AU2022208241A1/en active Pending
- 2022-01-14 US US18/271,913 patent/US20240082244A1/en active Pending
- 2022-01-14 KR KR1020237023066A patent/KR20230133285A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022208241A9 (en) | 2025-01-09 |
| JP2024505630A (ja) | 2024-02-07 |
| GB202100526D0 (en) | 2021-03-03 |
| EP4277606A1 (en) | 2023-11-22 |
| AU2022208241A1 (en) | 2023-07-06 |
| US20240082244A1 (en) | 2024-03-14 |
| CN116710077A (zh) | 2023-09-05 |
| CA3202029A1 (en) | 2022-07-21 |
| WO2022153062A1 (en) | 2022-07-21 |
| KR20230133285A (ko) | 2023-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013194A (es) | Compuesto inhibidor de atr que contiene sulfoximina. | |
| MX2023012725A (es) | Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos. | |
| UY39296A (es) | Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| CL2019003610A1 (es) | Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477). | |
| SV2007002427A (es) | Una formulacion solida de dosificacion farmaceutica | |
| HN2012001162A (es) | Triazolopiridinas | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| MX2018015709A (es) | Derivados de azabencimidazol como inhibidores de pi3k beta. | |
| MX2023008406A (es) | Formulacion farmaceutica. | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| MX2025011559A (es) | Rendimiento mejorado de formulaciones solidas amorfas y solubilizadas para lograr concentraciones plasmaticas terapeuticas | |
| MX2023002117A (es) | Forma amorfa de un inhibidor de malt1 y formulaciones de este. | |
| MX2018008772A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| MX2015016971A (es) | Formulacion que comprende un agente hipolipidemico. | |
| CO6321158A2 (es) | Formulacion oral | |
| DOP2022000035A (es) | Composiciones que comprenden tigolaner para el control de parásitos | |
| ZA202210629B (en) | Pharmaceutical composition comprising benzimidazole derivative compound | |
| MX2025006915A (es) | Preparación farmacéutica de un compuesto de imidazolinona, método de preparación y uso de esta | |
| MX2024011130A (es) | Inhibidor de derivados heterociclicos que contienen nitrogeno, metodo de preparacion y utilizacion del mismo | |
| MX2021002260A (es) | Compuestos utiles como moduladores de la autofagia mediada por chaperonas. | |
| CL2024002379A1 (es) | Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso | |
| AR112217A1 (es) | Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta | |
| MX383032B (es) | Formulaciones farmaceuticas inyectables de lefamulina. | |
| HN2012001923A (es) | Hidrato del hidrocloruro de agomelatina y preparacopn de este |